Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Licenses Linear RNA Amplification Technology to Ambion

NEW YORK, Feb. 15-Ambion has established a non-exclusive license from Incyte Genomics to manufacture and sell kits based on linear RNA amplification technology, the companies said today.


The firms did not disclose the financial terms of the agreement.


Linear RNA amplification technology is an antisense method that increases cellular RNA expression in order to reveal gene expression patterns. This particular technique uses a series of enzymatic reactions to amplify small amounts of RNA, a process that may create a more accurate portrait of relative mRNA ratios.


Ambion's aRNA kit is capable of 1,000x RNA amplification, according to the company. A 20-reaction kit retails in the United States for $795.


The company has been selling the kit since last fall, said Ambion president Bruce Leander, and sales have been "absolutely fantastic."


"RNA amplification is a hot area," he said. "Researchers are very interested in expression and regulation, and the ability to amplify RNA is increasingly important."


Ambion, a privately held company that specializes in RNA products and technologies, is based in Austin, Tex.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.